Logothetis CJ - Search Results

1

Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.

Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Zhang W, et al. Among authors: logothetis cj. Clin Cancer Res. 2018 Feb 1;24(3):696-707. doi: 10.1158/1078-0432.CCR-17-1872. Epub 2017 Nov 14. Clin Cancer Res. 2018. PMID: 29138344 Free PMC article.

2

Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer.

McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ. McDonnell TJ, et al. Among authors: logothetis cj. J Urol. 1997 Feb;157(2):569-74. J Urol. 1997. PMID: 8996359

3

Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer.

Tu SM, Pagliaro LC, Banks ME, Amato RJ, Millikan RE, Bugazia NA, Madden T, Newman RA, Logothetis CJ. Tu SM, et al. Among authors: logothetis cj. Clin Cancer Res. 1998 May;4(5):1193-201. Clin Cancer Res. 1998. PMID: 9607577 Clinical Trial.

4

Structural alterations of chromosome 5 in twelve human prostate cancer cell lines.

Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S. Ozen M, et al. Among authors: logothetis cj. Cancer Genet Cytogenet. 1998 Oct 15;106(2):105-9. doi: 10.1016/s0165-4608(98)00051-x. Cancer Genet Cytogenet. 1998. PMID: 9797773

5

Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.

Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A, Logothetis CJ. Ellerhorst JA, et al. Among authors: logothetis cj. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2371-6. Clin Cancer Res. 1997. PMID: 9815636 Clinical Trial.

6

Establishment of two human prostate cancer cell lines derived from a single bone metastasis.

Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Navone NM, et al. Among authors: logothetis cj. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2493-500. Clin Cancer Res. 1997. PMID: 9815652

7

p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential.

Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. Navone NM, et al. Among authors: logothetis cj. J Urol. 1999 Jan;161(1):304-8. J Urol. 1999. PMID: 10037428

8

Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma.

Kim J, Logothetis CJ. Kim J, et al. Among authors: logothetis cj. Urol Clin North Am. 1999 May;26(2):281-90. doi: 10.1016/s0094-0143(05)70068-9. Urol Clin North Am. 1999. PMID: 10361551 Review.

9

Model systems of prostate cancer: uses and limitations.

Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Navone NM, et al. Among authors: logothetis cj. Cancer Metastasis Rev. 1998-1999;17(4):361-71. doi: 10.1023/a:1006165017279. Cancer Metastasis Rev. 1998. PMID: 10453280 Review.

10

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results.

Pettaway CA, Pisters LL, Troncoso P, Slaton J, Finn L, Kamoi K, Logothetis CJ. Pettaway CA, et al. Among authors: logothetis cj. J Clin Oncol. 2000 Mar;18(5):1050-7. doi: 10.1200/JCO.2000.18.5.1050. J Clin Oncol. 2000. PMID: 10694556 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

423 results

Search Page

Filters